StreetInsider.com News Articles

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Wed, 07 Oct 2026 08:00:00 -0400

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS

Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis

EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for presentation

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Wed, 07 Oct 2026 08:00:00 -0400

Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis

H.C. Wainwright Reiterates Buy Rating on Kyverna Therapeutics Inc (KYTX)

Fri, 25 Sep 2026 06:48:01 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Kyverna Therapeutics Inc (NASDAQ: KYTX).

The analyst commented: "Kyverna reported that all 26 KYSA-8 patients reached one-year follow-up, with a 49% median T25FW improvement from baseline vs. 46% at Week 16; 95% of the 81% who initially achieved a ≥20% improvement retained that benefit, eight of 12 baseline walking-aid users remained unassisted, and 24/26 patients remained off protocol-defined stiff-person syndrome (SPS) immunotherapies. We believe the dataset answers the durability question that had been the principal clinical variable ahead of rolling Biologics License Application (BLA) completion, yet

Kyverna stock jumps on positive one-year therapy data

Thu, 24 Sep 2026 09:43:31 -0400

Investing.com -- Kyverna Therapeutics Inc (NASDAQ:KYTX) shares rose nearly 10% in early trade Thursday following the release of positive one-year durability data for its miv-cel therapy in stiff person syndrome and generalized myasthenia gravis.

The company reported that sustained clinical benefit and reversal of disability through one year support the potential for miv-cel to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease. The rolling BLA submission remains on track for completion in the fourth quarter of 2026.

In the KYSA-8 SPS registrational trial, 12-month follow-up data

Kyverna stock jumps on positive one-year therapy data

Thu, 24 Sep 2026 09:43:31 -0400

In the KYSA-8 SPS registrational trial, 12-month follow-up data

Form 8-K Kyverna Therapeutics, For: Sep 24

Thu, 24 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260924/27098415.html

Kyverna reports one-year durability data for miv-cel in SPS and gMG

Thu, 24 Sep 2026 06:01:54 -0400

Kyverna Therapeutics (Nasdaq: KYTX) released one-year topline data from its KYSA-8 registrational trial of miv-cel (mivocabtagene autoleucel) in stiff person syndrome (SPS) and longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG), according to a company statement.

In the KYSA-8 trial, 26 adult SPS patients received a single dose of miv-cel. As of a database lock in July 2026, the timed 25-foot walk showed a median improvement from baseline of 49% at month 12, compared with 46% at week 16. Of 12 patients who required a walking aid prior to treatment, 67% continued

Kyverna reports one-year durability data for miv-cel in SPS and gMG

Thu, 24 Sep 2026 06:01:54 -0400

Kyverna reports one-year durability data for miv-cel in SPS and gMG

Thu, 24 Sep 2026 06:01:54 -0400

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Thu, 24 Sep 2026 06:00:00 -0400

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct

Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026

Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE;
Phase 3 enrollment expected to be completed

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Thu, 24 Sep 2026 06:00:00 -0400

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct

Sustained clinical benefit and reversal of disability through one year support the potential to be the first approved therapy in SPS and first approved CAR T-cell therapy for autoimmune disease; rolling BLA submission on track for completion in Q4 2026

Longer-term Phase 2 follow-up in gMG demonstrate robust and durable effects sustained for up to 1.5 years, with majority of patients maintaining MSE;
Phase 3 enrollment expected to be completed

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:

2026 Wells Fargo Healthcare Conference
Format: Fireside chat and investor meetings
Date: Wednesday, September 9^th, 2026
Time: 4:30 p.m. ET

Morgan Stanley 24^th Annual Global Healthcare Conference
Format: Fireside chat and investor meetings
Date: Monday, September 14^th, 2026
Time: 4:05 p.m. ET

H.C. Wainwright 28^th Annual Global Investment Conference
Format: Fireside chat and investor meetings
Date:

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Wed, 02 Sep 2026 16:05:00 -0400

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:

2026 Wells Fargo Healthcare Conference
Format: Fireside chat and investor meetings
Date: Wednesday, September 9^th, 2026
Time: 4:30 p.m. ET

Morgan Stanley 24^th Annual Global Healthcare Conference
Format: Fireside chat and investor meetings
Date: Monday, September 14^th, 2026
Time: 4:05 p.m. ET

H.C. Wainwright 28^th Annual Global Investment Conference
Format: Fireside chat and investor meetings
Date:

Form SCHEDULE 13G/A Kyverna Therapeutics, Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260814/26924416.html

Form SCHEDULE 13G/A Kyverna Therapeutics, Filed by: Bain Capital Life Sciences Opportunities III, LP

Fri, 14 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260814/26924416.html

Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c

Tue, 11 Aug 2026 17:14:54 -0400

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) reported Q2 EPS of ($0.63), $0.45 better than the analyst estimate of ($1.08).
For earnings history and earnings-related data on Kyverna Therapeutics, Inc. (KYTX) click here.

Form 10-Q Kyverna Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26905709.html

Form 10-Q Kyverna Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260811/26905709.html

Form 8-K Kyverna Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260811/26905548.html

Form 8-K Kyverna Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260811/26905548.html

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:02:00 -0400

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology

On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026

Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026

Reiterates operating runway into 2028

EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:02:00 -0400

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology

On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026

Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026

Reiterates operating runway into 2028

EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:02:00 -0400

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology

On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026

Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026

Reiterates operating runway into 2028

EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:02:00 -0400

FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology

On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026

Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026

Reiterates operating runway into 2028

EMERYVILLE, Calif., Aug. 11, 2026 (GLOBE

Form SCHEDULE 13G Kyverna Therapeutics, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:22:00 -0400
si-local-file:///var/storage/secattach/20260729/26834375.html